6SE-78587-35080
3 vaccinations
1 coded response
22 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 26-30
- ZIP prefix
- 782 / TX
- Registered
- 2020-12-18
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-18
Registered in v-safe
-
2020-12-18
Dose 1 — Pfizer-BioNTech
- 2020-12-18
- 2020-12-19
- 2020-12-20
- 2020-12-21
- 2020-12-22
- 2020-12-27
- 2021-01-01
- 2021-01-08
-
2021-01-11
Dose 2 — Pfizer-BioNTech
- 2021-01-15
- 2021-01-16
- 2021-01-17
- 2021-01-18
- 2021-01-25
- 2021-02-01
- 2021-02-08
- 2021-02-15
- 2021-02-22
- 2021-04-12
- 2021-07-12
-
2021-10-30
Dose 3 — Moderna
-
2022-01-11
Survey response — 12 months, dose 2MedDRA: Cough, Dysphonia, Oropharyngeal pain, Respiratory tract congestion, Rhinorrhoea — Feeling: Good · Be unable to work or attend schoolFree text: Cough, sore throat, rhinorrhea, congestion, hoarse voiceMedDRA releases: 2024-11 · check-in free text available
- 2022-04-30
- 2022-10-30
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-18 | Pfizer-BioNTech | |
| 2 | 2021-01-11 | Pfizer-BioNTech | |
| 3 | 2021-10-30 | Moderna | No |
Free text
Release 10 — 12 months, dose 2
Symptoms: Cough, sore throat, rhinorrhea, congestion, hoarse voice
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Cough | · | · | ✓ |
| SD | Dysphonia | · | · | ✓ |
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Respiratory tract congestion | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release